Faron Pharmaceuticals

0.49 EUR

+3.24 %

5,707 following
Corporate customer

FARON

First North Finland

Biotechnology & Pharmaceuticals

Health Care

+3.24 %
-2.28 %
-15.26 %
-75.27 %
-76.41 %
-79.87 %
-84.94 %
-88.05 %
-85.22 %

Faron is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments.

Read more
Market cap
100.2M EUR
Turnover
186.83K EUR
P/E (adj.) (26e)
-4.78
EV/EBIT (adj.) (26e)
-5.51
P/B (26e)
85.64
EV/S (26e)
26,180.92
Dividend yield-% (26e)
-
Coverage
Recommendation
Buy
Target price
0.75 EUR
Updated
2026-03-11
Disclaimer
Antti Siltanen
Antti Siltanen

Analyst

Latest research

Latest analysis report

Released: 2026-03-12

Latest extensive report

Released: 2022-08-23

Revenue and EBIT-%

Revenue K

EBIT-% (adj.)

EPS and dividend

EPS (adj.)

Dividend %

Financial calendar
26/8
2026

Interim report Q2'26

Risk
Business risk
Valuation risk
Low
High
ShowingAll content types

Join Inderes community

Don't miss out - create an account and get all the possible benefits

Inderes account
Followings and notifications on followed companies
Analyst comments and recommendations
Stock comparison tool & other popular tools
Create account
Forum discussions
https://thebrilliantbiotechboss.substack.com/p/when-translation-overruns-great-science?r=nftvj The story of CD47 is increasingly looking like the biology was right, but the approach was too simple. Gilead paid 4.9 billion for Forty Seven and Pfizer paid 2.3 billion for Trillium, ...
8 hours ago
by poiju
34
Even though no names are mentioned, it is clear that this article plays right into Bex’s hands. It is worth noting and appreciating the quality of that publication (Nature Cancer). When scientists from a “small shop” (AstraZeneca) like that submitted their article for publication...
yesterday
by Kulkuri
28
Those results are Phase Ib. Faron is slightly further along in the clinical research phases. Furthermore, the mechanisms of action for Oryzon’s and Faron’s drug candidates differ.
5/18/2026, 7:45 AM
by tomtom
21
CLEVER-1 and bex have been referenced in publications by Hollmén et al. and Virtakoivu et al., stating that it is a promising early-stage PoC (Proof of Concept). One probably couldn’t say much more or better than that.
yesterday
by hawk_
19
Great! From the link in the image, you can open the full article for free: https://www.nature.com/articles/s43018-026-01159-6.epdf?sharing_token=iHkjMRYXVnWxQvsO8XSNS9RgN0jAjWel9jnR3ZoTv0PYAE8en-KIAFDR-pso6tjEiEy_45jyYu3gdXSX555ResOWeArKL5aRcYcec_0Mk8Komg_TSI2gTTdMH4Uec-Kj9qRJccOaeF4XMjUL3...
yesterday
by Kulkuri
19
LinkedIn #mds #myelodysplasticsyndrome #hematology #myeloidcells #bexmarilimab... 🔬 A new review in Nature Cancer argues that myeloid cell plasticity, not just heterogeneity, is one of the defining barriers in cancer therapy. In MDS, where the disease originates from within the myeloid...
yesterday
by marmot76
18
Great find, Here is also a LinkedIn post from a friend on the subject; the old way of thinking is no longer sufficient, new methods are needed: “targeting one suppressive population often leads to compensatory expansion of another” “The goal is not to eliminate myeloid cells but ...
yesterday
by Makkispekkis1
17
Read more on our forum

Inderes’ Disclaimer can be found here. Detailed information about each share actively monitored by Inderes is available on the company-specific pages on Inderes’ website. © Inderes Oyj. All rights reserved.